Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : wla(warner lambert) -- Ignore unavailable to you. Want to Upgrade?

To: Quonnie who wrote (358)	10/9/1998 8:57:00 PM
From: Anthony Wong	Respond to of 942

Quonnie, PFE and JNJ both reporting next week. I posted 2 Bloomberg earnings preview articles at the Pharma News thread and also at PFE's thread. Other good news, Viagra scripts for week ened Oct. 2 are up. Next week looks good for pharma stocks. I already have PFE, but intend to buy some more next Monday as a trade. Regards. Anthony

To: Quonnie who wrote (358)	10/16/1998 11:55:00 AM
From: Anthony Wong	Read Replies (1) \| Respond to of 942

Warner-Lambert 3rd-Qtr Profit Seen at 34C/Shr: Earnings Outlook Bloomberg News October 15, 1998, 6:26 p.m. ET Expected Earnings Warner-Lambert Co.'s third-quarter earnings are expected to rise to 34 cents a share from 24 cents a share, adjusted for a three-for-one stock split, based on the average estimate of analysts surveyed by First Call Corp. Time Morris Plains, New Jersey-based Warner-Lambert plans to release its earnings Monday morning. Behind the Numbers Sales of two drugs, the cholesterol reducer Lipitor and diabetes pill Rezulin, are boosting Warner-Lambert's profit. Warner-Lambert introduced both of these drugs in 1997. Lipitor has been taking sales from Merck & Co.'s Zocor. Warner-Lambert had some setbacks in the third quarter. Its prostate cancer drug Metaret failed Sept. 1 to win the backing of a U.S. Food and Drug Administration advisory panel. In July, Warner-Lambert said its diabetes drug Rezulin will carry new warnings about the risk of liver damage in a label agreed upon by the company and FDA. The new warnings mark the third time Rezulin's label has been strengthened since Warner-Lambert introduced the drug in 1997. What the Experts Say ''Lipitor and Rezulin, it's still those two horses that are driving the stock,'' said Erik Anderson, a portfolio manager with Sit Investment, which holds about 577,000 Warner-Lambert shares. Previous Market Reaction Warner-Lambert rose 3 9/16 to 83 1/8 on July 20 after reporting a 46 percent increase in second-quarter earnings. Market Performance Morris Plains, New Jersey-based Warner-Lambert rose 62 percent in the past year to 76. In the same period, the Standard & Poor's Health Care Diversified Index rose 34 percent and the Standard & Poor's 500 Index rose 8.5 percent. --Kerry Dooley in the Princeton newsroom (609) 279-4016 /mfr